Electrochemical Sensor for Real-Time Bioavailable Drug Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug delivery systems, such as computer-controlled infusion pumps, rely on pharmacokinetic models that do not account for individual patient responses, leading to inaccuracies in drug concentration and effect profiles, particularly in real-time adjustments.
Innovation Solution
Development of an electrochemical sensor with a coating comprising a structural component, a water immiscible organic solvent, and a charge transfer component, integrated into an indwelling catheter or microfluidic device, capable of detecting bioavailable drug concentrations in real-time to modulate drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Extent of automation
If pharmacokinetic models are used for drug delivery control, then automated drug administration is achieved, but individual patient response variability cannot be accounted for
Solution Approach 1:
The patent implements real-time feedback control by continuously measuring bioavailable drug concentration in the patient's bloodstream and using this information to adjust the infusion rate. The sensor provides direct feedback about the actual drug level, allowing the system to adapt to individual patient responses rather than relying solely on predetermined pharmacokinetic models.
Solution Approach 2:
The patent replaces the theoretical pharmacokinetic model with direct electrochemical measurement of drug concentration. Instead of calculating expected drug levels based on population averages and mathematical models, the system directly measures the actual bioavailable concentration using an electrochemical sensor, substituting mechanical/mathematical modeling with direct physical measurement.
2Measurement precision
If real-time drug concentration detection is implemented, then individualized drug delivery control is achieved, but device complexity increases
Solution Approach 1:
The patent combines the drug delivery pump and the electrochemical sensor into a single integrated system. The sensor is positioned within the infusion line or catheter, allowing simultaneous drug administration and concentration measurement without requiring separate external monitoring equipment. This merging reduces overall system complexity despite the advanced measurement capability.
Solution Approach 2:
The patent uses an electrochemical sensor as an intermediary device that translates biochemical drug concentration information into electrical signals that can be processed by the control system. This intermediary converts complex biological information into simple voltage or current measurements, simplifying the interface between the biological system and the automated control mechanism.
3Extent of automation
If traditional infusion pumps are used, then drug delivery automation is provided, but real-time adjustment based on actual drug levels is not possible
Solution Approach 1:
The system implements closed-loop feedback control where the electrochemical sensor continuously monitors bioavailable drug concentration and feeds this information back to the infusion pump controller. This allows real-time adjustment of the infusion rate based on actual measured drug levels, enabling the system to adapt to changing patient conditions and maintain target drug concentrations dynamically.
Solution Approach 2:
The patent transforms the static, predetermined infusion protocol into a dynamic control system that continuously adapts to real-time conditions. The infusion rate is no longer fixed or based on pre-calculated schedules but is dynamically adjusted according to live sensor measurements, allowing the system to respond flexibly to individual patient pharmacokinetics and pharmacodynamics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables precise, real-time adjustment of drug delivery based on actual bioavailable drug concentrations, improving treatment efficacy and safety by overcoming limitations of traditional pharmacokinetic models.
Implementation Method 1
the coating selectively partitions an electrochemically active drug such that an oxidation/reduction current within the coating can be measured
Implementation Method 2
an oxidation/reduction current within the coating can be measured (via the two or more electrodes)
Data Source
AI summary
The invention relates to a method for the controlled delivery of a drug as a function of bioavailable drug concentration, a sensor device for detecting bioavailable drug concentration, and a delivery device that controls delivery of the drug based on the real-time detection of bioavailable drug concentration.